Diabetic Retinopathy - A US Market Report - new market research report published
2012-12-01 00:04:31 - Diabetic Retinopathy - A US Market Report - a new market research report on companiesandmarkets.com
The US Diabetic Retinopathy Market will Exceed $540 Million by 2015. Diabetic retinopathy is a fashion of eye disease that occurs in people suffering from diabetes, governing to severe vision loss, and in some cases, even total blindness. Diabetic retinopathy is a collective entitle given to diverse abnormalities associated with retinal small blood vessels that are inflicted by diabetes.Vision loss
due to diabetic retinopathy is caused by pair conditions: Diabetic Macular Edema is a form of non-proliferative diabetic retinopathy where fluid enters the macula, causing it to swell and thus tend the vision blurred. Proliferative Diabetic Retinopathy is the final stage of diabetic retinopathy, in which place problems with circulation of blood cause certain retinal areas to change to ischemic (deprived of oxygen). Proliferative Diabetic Retinopathy is a major create of vision loss in patients with diabetic retinopathy.According to Global Industry Analysts, drug therapy as antidote to diabetic retinopathy, however, is no longer a dubious proposition. Drugs of that kind as Arxxant (Eli Lilly), Atacand (Astra Zeneca), Lucentis (Genentech/Novartis), Avastin (Genetech/Roche) and Dexamethasone are every one of in their late stage development; and some of these drugs are expected to enter the market in the next few years. These drugs, when approved, would open new doors for the treatment of diabetic retinopathy, a disease that is soon being managed only by preventive measures and surgical intervention.This report analyzes the US Market for Diabetic Retinopathy in US$ Million. Annual estimates and forecasts are provided for the period 2011 through 2015. The report profiles 40 companies including many key and niche players such as Allergan, Inc., AstraZeneca PLC., Eyetech, Inc., Fovea Pharmaceuticals SA, Genentech, Inc., Gene Signal, Isis Pharmaceuticals, Inc., Lpath, Inc., MacuSight, Inc., OM Pharma S.A, OPKO Health, Inc., Oxford BioMedica Plc., pSivida Corp., Quark Pharmaceuticals, Inc., Sanwa Kagaku Kenkyusho Co., Ltd., Sirnaomics, Inc., Suzuken Co., Ltd., and Vitreoretinal Technologies, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. Global Industry Analysts ©
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.